Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00038922|
Recruitment Status : Terminated
First Posted : June 7, 2002
Last Update Posted : May 18, 2006
To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis.
To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.
|Condition or disease||Intervention/treatment||Phase|
|Ulcerative Colitis Inflammatory Bowel Disease||Drug: rhIL-11||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Safety and Exploratory Pharmacogenomic Study of Orally Administered Recombinant Human Interleukin Eleven (rhIL-11) in Patients With Mild to Moderate Left-Sided Ulcerative Colitis|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00038922
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|